CoChat

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

Open access

Abstract

The tau positron emission tomography (PET) ligand 18 F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer’s disease (AD), but its utility in detecting tau aggregates in frontotemporal dementia (FTD) is uncertain. We performed 18 F-flortaucipir imaging in patients with the FTD syndromes ( n = 45): nonfluent variant primary progressive aphasia (nfvPPA) ( n = 11), corticobasal syndrome (CBS) ( n = 10), behavioral variant frontotemporal dementia (bvFTD) ( n = 10), semantic variant primary progressive aphasia (svPPA) ( n = 2) and FTD associated pathogenic genetic mutations microtubule-associated protein tau ( MAPT ) ( n = 6), chromosome 9 open reading frame 72 ( C9ORF72 ) ( n = 5), and progranulin ( GRN ) ( n = 1). All patients underwent MRI and β-amyloid biomarker testing via 11 C-PiB or cerebrospinal fluid. 18 F-flortaucipir uptake in patients was compared to 53 β-amyloid negative normal controls using voxelwise and pre-specified region of interest approaches. On qualitative assessment, patients with nfvPPA showed elevated 18 F-flortacupir binding in the left greater than right inferior frontal gyrus. Patients with CBS showed elevated binding in frontal white matter, with higher cortical gray matter uptake in a subset of β-amyloid-positive patients. Five of ten patients with sporadic bvFTD demonstrated increased frontotemporal binding. MAPT mutation carriers had elevated 18 F-flortaucipir retention primarily, but not exclusively, in mutations with Alzheimer’s-like neurofibrillary tangles. However, tracer retention was also seen in patients with svPPA, and the mutations C9ORF72 , GRN predicted to have TDP-43 pathology. Quantitative region-of-interest differences between patients and controls were seen only in inferior frontal gyrus in nfvPPA and left insula and bilateral temporal poles in MAPT carriers. No significant regional differences were found in CBS or sporadic bvFTD. Two patients underwent postmortem neuropathological examination. A patient with C9ORF72 , TDP-43-type B pathology, and incidental co-pathology of scattered neurofibrillary tangles in the middle frontal, inferior temporal gyrus showed corresponding mild 18 F-flortaucipir retention without additional uptake matching the widespread TDP-43 type B pathology. A patient with sporadic bvFTD demonstrated punctate inferior temporal and hippocampus tracer retention, corresponding to the area of severe argyrophilic grain disease pathology. 18 F-flortaucipir in patients with FTD and predicted tauopathy or TDP-43 pathology demonstrated limited sensitivity and specificity. Further postmortem pathological confirmation and development of FTD tau-specific ligands are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-019-0470-7

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 18F-flortaucipir in nfvPPA. a Voxel-wise contrast (pFWE< 0.05) of 11 nfvPPA patients with 53 normal controls with age as covariate. b W-score frequency map showing number of patients with suprathreshold age-adjusted SUVR values (w-score ≥ 1.65) compared to normal controls. Peak voxels suggest eight of 11 subjects have elevated w-score voxels in the same region. c 18F-flortaucipir SUVR values for each pre-specified region of interest; horizontal bar denotes mean. L, left; NC, normal control; SF, superior frontal. ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05
Fig. 1 18F-flortaucipir in nfvPPA. a Voxel-wise contrast (pFWE< 0.05) of 11 nfvPPA patients with 53 normal controls with age as covariate. b W-score frequency map showing number of patients with suprathreshold age-adjusted SUVR values (w-score ≥ 1.65) compared to normal controls. Peak voxels suggest eight of 11 subjects have elevated w-score voxels in the same region. c 18F-flortaucipir SUVR values for each pre-specified region of interest; horizontal bar denotes mean. L, left; NC, normal control; SF, superior frontal. ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05CC BY · PubMed Central
Fig. 2 18F-flortaucipir in CBS. a CBS-flortaucipir (+) example is a 71-year-old female patient, MMSE 29, CDR-SB 2.5, PiB positive. CBS-flortaucipir (−) example is a 60-year-old male patient, MMSE 26, CDR 1.5 PiB negative. CBS-AD example is a 70-year-old male patient, MMSE 25, CDR-SB 7, PiB positive. b Voxel-wise contrast of 18F-flortaucipir images in seven CBS patients (without CBS-AD images) with 53 normal controls with age as covariate. c W-score frequency map showing number of patients with suprathreshold age-adjusted SUVR values (w-score ≥ 1.65) compared to normal controls. Peak voxels suggest four of seven subjects have elevated w-score voxels in the same region. d 18F-flortaucipir SUVR values for each pre-specified region of interest; horizontal bar denotes mean. NC, normal control; CL, contralateral to symptom onset; IL, ipsilateral to symptom onset; CMF, caudal middle frontal; WM, white matter
Fig. 2 18F-flortaucipir in CBS. a CBS-flortaucipir (+) example is a 71-year-old female patient, MMSE 29, CDR-SB 2.5, PiB positive. CBS-flortaucipir (−) example is a 60-year-old male patient, MMSE 26, CDR 1.5 PiB negative. CBS-AD example is a 70-year-old male patient, MMSE 25, CDR-SB 7, PiB positive. b Voxel-wise contrast of 18F-flortaucipir images in seven CBS patients (without CBS-AD images) with 53 normal controls with age as covariate. c W-score frequency map showing number of patients with suprathreshold age-adjusted SUVR values (w-score ≥ 1.65) compared to normal controls. Peak voxels suggest four of seven subjects have elevated w-score voxels in the same region. d 18F-flortaucipir SUVR values for each pre-specified region of interest; horizontal bar denotes mean. NC, normal control; CL, contralateral to symptom onset; IL, ipsilateral to symptom onset; CMF, caudal middle frontal; WM, white matterCC BY · PubMed Central
Fig. 3 18F-flortaucipir in MAPT mutation carriers. a 18F-flortaucipir images and corresponding single-subject w-score maps in the following: (1) A 66-year-old V337 M carrier, MMSE 20, CSF Aβ negative. (2) A 68-year-old with R406W mutation, MMSE 16, PiB negative. (3) A 67-year-old P301L carrier, MMSE 5, PiB positive. (4) A 37-year-old S305I carrier, MMSE 4, PiB negative. (5) A 44-year-old IVS10 + 16 carrier, MMSE 30, PiB negative. (6) A 58-year-old IVS10 + 16 carrier, MMSE 27, PiB negative. b 18F-flortaucipir SUVR values for each pre-specified region of interest; horizontal bar denotes mean. L, left; NC, normal control; CDR-SB, Clinical Dementia Rating scale sum of boxes. *p ≤ 0.05
Fig. 3 18F-flortaucipir in MAPT mutation carriers. a 18F-flortaucipir images and corresponding single-subject w-score maps in the following: (1) A 66-year-old V337 M carrier, MMSE 20, CSF Aβ negative. (2) A 68-year-old with R406W mutation, MMSE 16, PiB negative. (3) A 67-year-old P301L carrier, MMSE 5, PiB positive. (4) A 37-year-old S305I carrier, MMSE 4, PiB negative. (5) A 44-year-old IVS10 + 16 carrier, MMSE 30, PiB negative. (6) A 58-year-old IVS10 + 16 carrier, MMSE 27, PiB negative. b 18F-flortaucipir SUVR values for each pre-specified region of interest; horizontal bar denotes mean. L, left; NC, normal control; CDR-SB, Clinical Dementia Rating scale sum of boxes. *p ≤ 0.05CC BY · PubMed Central
Fig. 4 18F-flortaucipir in bvFTD. a Five bvFTD scans and corresponding single-subject w-score maps determined to have clear uptake signal in frontal and temporal lobes. Patient 1 is a 46-year-old male, MMSE 22, CDR-SB 4, PiB negative. Patient 2 is a 54-year-old female, MMSE 19, CDR-SB 5, PiB negative. Patient 3 is a 74-year-old male with MMSE 23, CDR-SB 7.5, PiB positive. Patient 4 is a 69-year-old male, MMSE 22, CDR-SB 9, PiB positive. Patient 5 is a 78-year-old female, MMSE 18, CDR-SB 12, PiB positive. b Five bvFTD scans and corresponding single-subject w-score maps determined to have minimal or no uptake in frontal and temporal lobes. Patient 6 is a 76-year-old male, MMSE 26, CDR-SB 6.5, PiB negative. Patient 7 is a 74-year-old male, MMSE 26, CDR-SB 1.5, PiB negative. Patient 8 is a 64-year-old male, MMSE 27, CDR-SB 7.5, PiB negative. Patient 9 is a 68-year-old male, MMSE 29, CDR-SB 5, PiB negative. Patient 10 is a 34-year-old male, MMSE 22, CDR-SB 8, Aβ status unavailable. c 18F-flortaucipir SUVR values for each pre-specified region of interest; horizontal bar denotes mean. L, left; NC, normal control
Fig. 4 18F-flortaucipir in bvFTD. a Five bvFTD scans and corresponding single-subject w-score maps determined to have clear uptake signal in frontal and temporal lobes. Patient 1 is a 46-year-old male, MMSE 22, CDR-SB 4, PiB negative. Patient 2 is a 54-year-old female, MMSE 19, CDR-SB 5, PiB negative. Patient 3 is a 74-year-old male with MMSE 23, CDR-SB 7.5, PiB positive. Patient 4 is a 69-year-old male, MMSE 22, CDR-SB 9, PiB positive. Patient 5 is a 78-year-old female, MMSE 18, CDR-SB 12, PiB positive. b Five bvFTD scans and corresponding single-subject w-score maps determined to have minimal or no uptake in frontal and temporal lobes. Patient 6 is a 76-year-old male, MMSE 26, CDR-SB 6.5, PiB negative. Patient 7 is a 74-year-old male, MMSE 26, CDR-SB 1.5, PiB negative. Patient 8 is a 64-year-old male, MMSE 27, CDR-SB 7.5, PiB negative. Patient 9 is a 68-year-old male, MMSE 29, CDR-SB 5, PiB negative. Patient 10 is a 34-year-old male, MMSE 22, CDR-SB 8, Aβ status unavailable. c 18F-flortaucipir SUVR values for each pre-specified region of interest; horizontal bar denotes mean. L, left; NC, normal controlCC BY · PubMed Central
Fig. 5 18F-flortaucipir in C9ORF72, GRN mutation carriers and svPPA. a Five C9ORF72 carriers scanned with 18F-flortaucipir and corresponding single-subject w-score maps. Patient 1 is 71 years old, MMSE 26, CDR-SB 1, PiB negative. Patient 2 is 67 years old, MMSE 22, CDR-SB 8, Aβ status unavailable. Patient 3 is 48 years old, MMSE 26, CDR-SB 7, PiB negative. Patient 4 is 54 years old, MMSE 26, CDR-SB 7, PiB negative. Patient 5 is 71 years old, MMSE 26, CDR-SB 0.5 PiB negative. b GRN mutation carrier with corresponding structural MRI and single-subject w-score map, 55 years old, MMSE 21, CDR-SB 4.5, PiB positive. Structural MRI demonstrates asymmetrical left hemispheric atrophy corresponding to location of tracer uptake. c Two svPPA patients with corresponding single-subject w-score maps. Patient 1 is a 59-year-old female, MMSE 28, CDR-SB 3.5, PiB negative. Patient 2 is a 71-year-old male, MMSE 25, CDR-SB 3.5, PiB negative. d 18F-flortaucipir SUVR values for patients with C9ORF72 and GRN mutations (C9 + P), for each pre-specified region of interest. e 18F-flortaucipir SUVR values for patients with svPPA for each pre-specified region of interest; horizontal bar denotes mean. L, left; NC, normal control; FTP, 18F-flortaucipir; *p ≤ 0.05
Fig. 5 18F-flortaucipir in C9ORF72, GRN mutation carriers and svPPA. a Five C9ORF72 carriers scanned with 18F-flortaucipir and corresponding single-subject w-score maps. Patient 1 is 71 years old, MMSE 26, CDR-SB 1, PiB negative. Patient 2 is 67 years old, MMSE 22, CDR-SB 8, Aβ status unavailable. Patient 3 is 48 years old, MMSE 26, CDR-SB 7, PiB negative. Patient 4 is 54 years old, MMSE 26, CDR-SB 7, PiB negative. Patient 5 is 71 years old, MMSE 26, CDR-SB 0.5 PiB negative. b GRN mutation carrier with corresponding structural MRI and single-subject w-score map, 55 years old, MMSE 21, CDR-SB 4.5, PiB positive. Structural MRI demonstrates asymmetrical left hemispheric atrophy corresponding to location of tracer uptake. c Two svPPA patients with corresponding single-subject w-score maps. Patient 1 is a 59-year-old female, MMSE 28, CDR-SB 3.5, PiB negative. Patient 2 is a 71-year-old male, MMSE 25, CDR-SB 3.5, PiB negative. d 18F-flortaucipir SUVR values for patients with C9ORF72 and GRN mutations (C9 + P), for each pre-specified region of interest. e 18F-flortaucipir SUVR values for patients with svPPA for each pre-specified region of interest; horizontal bar denotes mean. L, left; NC, normal control; FTP, 18F-flortaucipir; *p ≤ 0.05CC BY · PubMed Central
Fig. 6 Positron emission tomography (PET) to autopsy comparisons. a 18F-flortaucipir standardized uptake value ratio (SUVR) images shown alongside corresponding histological slides for a 68-year-old man with behavioral variant frontotemporal dementia due to argyrophilic grain disease (AGD), a 4-repeat tauopathy and Braak Alzheimer’s disease stage 3. The red arrow denotes areas of signal uptake. b Histological slides across the hippocampus at the level of the lateral geniculate body immunostained for phospho-tau protein (Ser202, CP-13, 1:500, gift of Peter Davies). (i) CA1 sector showing abundant grains and few neurofibrillary tangles. (ii) CA 1 sector showing abundant grains and few neurofibrillary tangles. (iii) Subiculum showing grains and pretangles. (iv) Inferior temporal gyrus showing grains and pretangles. L, left
Fig. 6 Positron emission tomography (PET) to autopsy comparisons. a 18F-flortaucipir standardized uptake value ratio (SUVR) images shown alongside corresponding histological slides for a 68-year-old man with behavioral variant frontotemporal dementia due to argyrophilic grain disease (AGD), a 4-repeat tauopathy and Braak Alzheimer’s disease stage 3. The red arrow denotes areas of signal uptake. b Histological slides across the hippocampus at the level of the lateral geniculate body immunostained for phospho-tau protein (Ser202, CP-13, 1:500, gift of Peter Davies). (i) CA1 sector showing abundant grains and few neurofibrillary tangles. (ii) CA 1 sector showing abundant grains and few neurofibrillary tangles. (iii) Subiculum showing grains and pretangles. (iv) Inferior temporal gyrus showing grains and pretangles. L, leftCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Cited by

See all 165

Metadata

Authors
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O’Neil, J. P., Janabi, M., Baker, S., Lee, S. E., Perry, D. C., Bajorek, L., Karydas, A., Spina, S., Grinberg, L. T., Seeley, W. W., Ramos, E. M., Coppola, G., Gorno-Tempini, M. L., Miller, B. L., Rosen, H. J., Jagust, W., Boxer, A. L., & Rabinovici, G. D.
Affiliations
  • University of California, San Francisco (US)
  • Lawrence Berkeley National Laboratory (US)
  • University of California, Los Angeles (US)
Corresponding author
Tsai, Richard M.
Venue
Alzheimer's Research & Therapy
Published
2019-01-31
Volume
11
Issue
1
Pages
13-13
ISSN
1758-9193 (ISSN-L)
OpenAlex
W2914951750
Cited by
164
References
78
Citations by year
2026: 9 · 2025: 13 · 2024: 20 · 2023: 21 · 2022: 33 · 2021: 36 · 2020: 25 · 2019: 7
FWCI
20.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institute on Aging (K23AG055688, K23AG045289, K08AG052648, K24AG053435, P01AG019724, U01 AG052943, P50-AG023501, R01AG034570, R01AG038791)
  • National Institute of Neurological Disorders and Stroke (R01NS050915, U54NS092089)
  • National Institute on Deafness and Other Communication Disorders (K24DC015544)
  • Tau Consortium
  • Michael J. Fox Foundation for Parkinson's Research
  • Association for Frontotemporal Degeneration
  • Bluefield Project to Cure FTD
  • Consortium for Frontotemporal Dementia Research
  • State of California DHS Alzheimer's Disease Research Center of California (04-33516)
  • State of California DHS Alzheimer’s Disease Research Center of California (DHS04-33516)
  • Fondation pour la Recherche Médicale
  • Alzheimer's Association (AARF-16-443577)
  • UCSF PPG
  • UCSF-ADRC
  • John Douglas French Alzheimer's Foundation
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
18F-flortaucipir, tau PET, frontotemporal dementia, corticobasal syndrome, behavioral variant frontotemporal dementia, semantic dementia, MAPT mutations, C9orf72, gene regulatory networks, TDP-43 pathology, neurofibrillary tangles, paired helical filaments, amyloid-beta, postmortem neuropathology
MeSH terms
Adult, Aged, Aged, 80 and over, Carbolines, Contrast Media, Female, Humans, Male, Middle Aged, Cohort Studies, tau Proteins, Positron-Emission Tomography, Young Adult, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. https://app.cochat.ai/papers/10.1186/s13195-019-0470-7
The paper
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O’Neil, J. P., Janabi, M., Baker, S., Lee, S. E., Perry, D. C., Bajorek, L., Karydas, A., Spina, S., Grinberg, L. T., Seeley, W. W., Ramos, E. M., Coppola, G., Gorno-Tempini, M. L., . . . Rabinovici, G. D. (2019). 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-019-0470-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.